Monosodium alpha luminol

Drug Profile

Monosodium alpha luminol

Alternative Names: Galavit; GVT

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Center of Modern Medicine (Medicor)
  • Developer Bach Pharma
  • Class Antiallergics; Antineoplastics; Antiparkinsonians; Eye disorder therapies; Phthalazines; Radioprotectives; Small molecules; Sodium compounds
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Cancer; Female genital diseases; Immunological disorders; Inflammation
  • Phase III Breast cancer; Small cell lung cancer
  • Phase II Dry eyes; Hypersensitivity; Wounds
  • No development reported Ataxia telangiectasia; Chronic obstructive pulmonary disease; Glaucoma; Metabolic syndrome; Neurological disorders; Parkinson's disease; Radiation injuries

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ataxia-telangiectasia in USA (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ataxia-telangiectasia in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top